#NSCLC

[healthcaretechnologynews]

Biomarker driven segments of NSCLC - Yet to saturate with new approvals

Industry experts think that NSCLC space is rushed with so many approvals, yet it is a hot space for researchers, as NSCLC market has huge potential and even 1% market share is a piece of hot cake for the investors.

Currently, there are a total of 5 FDA-approved TKIs for frontline treatment in EGFR- positive NSCLC.

Though, recent data on frontline Osimertinib confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC)

Experts indicated that they would look forward to the novel approaches that are trying to enhance the activity of Osimertinib by targeting other oncogenic pathways in combination with anti-EGFR therapy.

Write to us at enquire@grgonline.com to learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

Chemotherapy is backbone to treat many types of cancers, and research continues to find new chemotherapy regimens in combination with novel drugs. Over a decade, NSCLC space has evolved immensely.

Even though NSCLC space has been bifurcated into many biomarkers driven patients’ segment with specific approval in these segments, still in upcoming years we will see more approvals in the space. Industry experts think that this space is rushed with so many drugs, yet it is a hot space for researchers, as NSCLC is a huge market and even a single percent market share is a piece of hot cake for the investors.

Currently there are a total of 5 FDA-approved TKIs for frontline treatment of EGFR- positive NSCLC. These include erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), Dacomitinib (Vizimpro), and Osimertinib (Tagrisso).

We have seen a lot of exciting data over the past couple years with regard to these agents as monotherapy or in combination. Despite the sequential efficacy of these FDA-approved EGFR TKIs, frontline Osimertinib confers the greatest progression-free survival (PFS) advantage for patients with EGFR-positive non–small cell lung cancer (NSCLC) recently.

Therefore, we still expect to see several studies moving forward with results reported out in the coming years. We expect an emergence of new biomarker driven segments also (for e.g., Novel combinations, certainly targeting VEGF or MET).

There are exciting ongoing studies targeting MET following progression on Osimertinib. Experts indicated that they would look forward to the novel approaches that are trying to enhance the activity of Osimertinib by targeting other oncogenic pathways in combination with anti-EGFR therapy.

Visit our website now: https://www.grgonline.com/

[healthcareporium]

Innovating Lung Cancer Care: Antibody-Drug Conjugates Lead the Way

The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate…

[medsforcancer8]

buy non-small cell lung cancer

[industryexperts]

(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)

The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.

[garnerbio]

PRESERVING THE PAST, DIAGNOSING THE FUTURE: FFPE BLOCKS IN CANCER TISSUE RESEARCH

FFPE tissue preservation involves two critical steps: fixation and embedding. The fixation process begins by immersing the tissue sample in formalin, a formaldehyde solution, which cross-links proteins and stabilizes cellular structures. This step is crucial as it prevents the degradation of tissue and preserves morphological details at the microscopic level

[perpetualseahorse]

Wtf tumblr

[futuretonext]

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide. 

[usnews23]

Perioperative Immunotherapy: A Promising Advancement in Early NSCLC Treatment

In recent years, the field of oncology has witnessed significant advancements in the treatment of various cancers, including non-small cell lung cancer (NSCLC). One such promising development is the utilization of perioperative immunotherapy, which has shown the potential in improving event-free survival (EFS) for early-stage NSCLC patients. In this comprehensive article, we explore the impact of…

[reasonsforhope]

"Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

The UK has six sites, located in England and Wales, with the first UK patient to receive the vaccine having their initial dose on Tuesday [August 20, 2024].

Overall, about 130 patients – from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer – will be enrolled to have the jab alongside immunotherapy. About 20 will be from the UK.

The jab uses messenger RNA (mRNA), similar to Covid-19 vaccines, and works by presenting the immune system with tumour markers from NSCLC to prime the body to fight cancer cells expressing these markers.

The aim is to strengthen a person’s immune response to cancer while leaving healthy cells untouched, unlike chemotherapy.

“We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer,” said Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK.

“It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.”

Janusz Racz, 67, from London, was the first person to have the vaccine in the UK. He was diagnosed in May and soon after started chemotherapy and radiotherapy.

The scientist, who specialises in AI, said his profession inspired him to take part in the trial. “I am a scientist too, and I understand that the progress of science – especially in medicine – lies in people agreeing to be involved in such investigations,” he said...

“And also, I can be a part of the team that can provide proof of concept for this new methodology, and the faster it would be implemented across the world, more people will be saved.”

Racz received six consecutive injections five minutes apart over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility on Tuesday.

Each jab contained different RNA strands. He will get the vaccine every week for six consecutive weeks, and then every three weeks for 54 weeks.

Lee said: “We hope adding this additional treatment will stop the cancer coming back because a lot of time for lung cancer patients, even after surgery and radiation, it does come back.” ...

“We hope to go on to phase 2, phase 3, and then hope it becomes standard of care worldwide and saves lots of lung cancer patients.”

The Guardian revealed in May that thousands of patients in England were to be fast-tracked into groundbreaking trials of cancer vaccines in a revolutionary world-first NHS “matchmaking” scheme to save lives.

Under the scheme, patients who meet the eligibility criteria will gain access to clinical trials for the vaccines that experts say represent a new dawn in cancer treatment."

-via The Guardian, May 30, 2024

[qyresearchmedica]

The global Non-Small Cell Lung Cancer (NSCLC) market size is expected to reach USD 13.51 Billion in 2030 and register a revenue CAGR of 6.8% during the forecast period.

[mindblowingscience]

The mRNA revolution continues. Just a few years after mRNA vaccines proved their efficacy against COVID-19, scientists are now turning their attention to lung cancer. The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries, including the United States and the United Kingdom. This vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

Continue Reading.

[mezzopieno-news]

APPROVATO IL FARMACO PER LA CURA DEL CARCINOMA POLMONARE

La Food and Drug Administration ha approvato il nuovo trattamento adiuvante dopo la resezione del tumore in pazienti con carcinoma polmonare non a piccole cellule (NSCLC) ALK positivo. Questo sottotipo di cancro del polmone è caratterizzato dalla presenza di una fusione o riarrangiamento genico che iperattiva la proteina ALK ed è una mutazione che rappresenta circa l’85% dei casi di carcinoma polmonare, il cui 5%risulta essere ALK positivo.

Il farmaco alectinib ha dimostrato la riduzione del rischio di recidiva della malattia o di morte rispetto alla chemioterapia ad un tasso del 76%, definito dai ricercatori “senza precedenti“, migliorando significativamente lo standard di cura per le persone affette da carcinoma polmonare ALK positivo in fase precoce. “L’approvazione di Alecensa segna un momento cruciale per le persone a cui è stato diagnosticato un tumore al polmone ALK positivo in fase iniziale che finora non potevano ricevere una terapia specifica”, ha dichiarato Ken Culver, direttore della ricerca e degli affari clinici di ALK Positive, Inc, una no-profit che si dedica a migliorare l’aspettativa dei pazienti in tutto il mondo. “Questi pazienti, che in genere ricevono la diagnosi in giovane età, vanno spesso incontro a recidive e hanno un rischio maggiore di sviluppare metastasi cerebrali rispetto a quelli affetti da altri tipi di NSCLC. Ora, con questo significativo progresso, è più importante che mai che tutte le persone a cui è stato diagnosticato un tumore al polmone in fase precoce si sottopongano al test per ALK e altri biomarcatori raccomandati per ricevere il trattamento più appropriato per loro”.

___________________

Fonte: Food and Drug Administration; ALK Positive Inc; foto di Anna Shvets

VERIFICATO ALLA FONTE | Guarda il protocollo di Fact checking delle notizie di Mezzopieno

BUONE NOTIZIE CAMBIANO IL MONDO | Firma la petizione per avere più informazione positiva in giornali e telegiornali

Se trovi utile il nostro lavoro e credi nel principio del giornalismo costruttivo non-profit | sostieni Mezzopieno

[justastarholder]

hey my dad just died from stage four lung cancer (NSCLC) and this story has kept me sane during this last week

can I get a hello from the gang? love yall!

"We know how hard it is to lose someone you care about. I'm so, so sorry for your loss. We're all here for you, starlight." -Eclipse

And from me, too, I am so sorry to hear what's happened. This drawing is far less than I wanted to give you but I really am glad you found some solace during these tough times in my silly little story. I am sending you much love and strength to pull through this. <3

[aquaticflames]

For the unpublished works ask game: 2, 10 and 15 for the oncology fic you mentioned, if you are so inclined!

hiii thank you for your interest!! 🫶💗

2. How did you get the idea to write this?

It spawned from two main angles of discussion about a year ago – a big conversation between some friends about the merits of bacta and it's largely unspoken about but theoretically probable drawbacks in use. I now hold a very firm stance on things it is fine to be used for, and things where it absolutely must be held at bay. Tangential to that, I wrote my dissertation at university about incidence of NSCLC and so was fairly eager to consider cancer in the bacta discussion, and here I am. Sitting with a monster of a WIP, haha.

10. If unpublished, can you show a sneak peek of what you've written?

Oooo okay!! I'll give you a snippet of the primary medics of the story. 🫶

15. Do you have any unwritten scene that you think about a lot?

Oo I'll do another one. One I think about a lot will be the build-up to O66, the crescendo before the chaos so to speak. By that point down the road things will have deviated a decent amount from canon's set-up for it, and I'm excited to play with those differences for the main three our lens will focus on; Obi-Wan, his much-needed primary medic Polymer, and Cody, hehe. The three of them are going to have quite a time...!

can't wait to have this one to a point where I can start sharing it! 💗🫶

[garnerbio]

Reliable Human Plasma Provider for Scientific and Medical Purposes

We are a top provider of superior human plasma, serving the needs of the scientific and medical sectors. To guarantee safety and effectiveness, our plasma is obtained from healthy donors, put through a rigorous testing process, and processed in accordance with tight criteria. Join together with us to get dependable, morally sourced human plasma that satisfies your demands.

[drforambhuta]

Targeted Therapy:

Precision or targeted therapies encompass medications engineered to disrupt specific molecules implicated in the progression of cancer. In contrast to conventional chemotherapy's broad impact on fast-dividing cells, precision therapies selectively target cancer cells while preserving healthy tissue integrity. These drugs aim at various molecular pathways involved in cancer development, including signaling cascades, angiogenesis, and DNA repair mechanisms.

An illustrative example of precision therapy is the application of tyrosine kinase inhibitors (TKIs) in treating specific cancer types like non-small cell lung cancer (NSCLC) and chronic myeloid leukemia (CML). TKIs hinder the activity of particular tyrosine kinases, crucial enzymes in cancer-promoting cell signaling pathways. By obstructing these kinases, TKIs effectively inhibit tumor growth and extend patient survival.

Likewise, monoclonal antibodies represent another form of precision therapy, binding to specific proteins on cancer cell surfaces, initiating immune-mediated tumor destruction. These antibodies can also be combined with cytotoxic agents or radioactive isotopes to heighten their anti-cancer properties.

Personalized Chemotherapy:

While precision therapies are central to personalized medicine, tailored chemotherapy remains vital in cancer treatment. Tailored chemotherapy involves customizing traditional cytotoxic drugs to suit the unique characteristics of each patient's tumor. This may involve adjusting drug doses, combining different agents, or selecting chemotherapy regimens based on tumor biology and patient-specific factors.

One approach to tailored chemotherapy utilizes predictive biomarkers to identify patients likely to respond positively to specific chemotherapy drugs. For example, certain mutations in the BRCA genes are associated with increased sensitivity to platinum-based chemotherapy in breast and ovarian cancers. By identifying these biomarkers, oncologists can identify patients who will benefit most from a particular chemotherapy regimen while minimizing potential toxicity for others.

Furthermore, progress in pharmacogenomics, which explores how genetic variations affect drug response, has provided insights into individual differences in drug metabolism and toxicity. By analyzing patients' genetic profiles, oncologists can predict their likelihood of experiencing adverse effects or poor response to chemotherapy drugs, enabling personalized dose adjustments and treatment optimization.

Early cancer detection and management is important for an improved success rate in cancer treatment. You can undergo regular health checkups to get diagnosed for cancer at an early-stage. There are many good hospitals in Mumbai that offer health checkup packages for cancer screening, such as a full body health checkup at Saifee Hospital Mumbai, which is one of the best hospitals in the country.